Elevance Health, Inc. $ELV Position Boosted by Artisan Partners Limited Partnership

Artisan Partners Limited Partnership boosted its holdings in Elevance Health, Inc. (NYSE:ELV) by 24.5% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 4,576,805 shares of the company’s stock after purchasing an additional 901,626 shares during the period. Elevance Health comprises approximately 2.1% of Artisan Partners Limited Partnership’s portfolio, making the stock its 8th largest holding. Artisan Partners Limited Partnership’s holdings in Elevance Health were worth $1,478,857,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also bought and sold shares of ELV. Nilsine Partners LLC lifted its position in Elevance Health by 1.5% in the third quarter. Nilsine Partners LLC now owns 1,918 shares of the company’s stock valued at $620,000 after purchasing an additional 29 shares during the last quarter. HBK Sorce Advisory LLC increased its stake in shares of Elevance Health by 4.4% in the third quarter. HBK Sorce Advisory LLC now owns 743 shares of the company’s stock worth $260,000 after buying an additional 31 shares during the period. Detalus Advisors LLC raised its holdings in Elevance Health by 1.8% during the 3rd quarter. Detalus Advisors LLC now owns 1,726 shares of the company’s stock valued at $558,000 after buying an additional 31 shares during the last quarter. Forum Financial Management LP boosted its position in Elevance Health by 1.1% during the 3rd quarter. Forum Financial Management LP now owns 2,971 shares of the company’s stock valued at $960,000 after buying an additional 33 shares during the period. Finally, Activest Wealth Management boosted its position in Elevance Health by 66.7% during the 3rd quarter. Activest Wealth Management now owns 85 shares of the company’s stock valued at $27,000 after buying an additional 34 shares during the period. 89.24% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research firms have issued reports on ELV. Deutsche Bank Aktiengesellschaft restated a “hold” rating and issued a $332.00 price objective on shares of Elevance Health in a research report on Thursday, January 29th. Weiss Ratings lowered Elevance Health from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Monday, February 2nd. Morgan Stanley dropped their price objective on Elevance Health from $359.00 to $352.00 and set an “equal weight” rating for the company in a report on Wednesday, December 17th. Wall Street Zen cut Elevance Health from a “buy” rating to a “hold” rating in a research note on Sunday, February 8th. Finally, UBS Group set a $400.00 target price on Elevance Health in a report on Thursday, January 29th. Twelve analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $390.55.

Elevance Health Price Performance

Shares of ELV opened at $322.94 on Friday. Elevance Health, Inc. has a fifty-two week low of $273.71 and a fifty-two week high of $458.75. The firm’s 50-day simple moving average is $350.62 and its two-hundred day simple moving average is $335.19. The stock has a market cap of $71.28 billion, a PE ratio of 12.86, a price-to-earnings-growth ratio of 1.83 and a beta of 0.50. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.54 and a current ratio of 1.54.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, January 28th. The company reported $3.33 EPS for the quarter, topping analysts’ consensus estimates of $3.10 by $0.23. Elevance Health had a return on equity of 15.59% and a net margin of 2.84%.The firm had revenue of $49.31 billion for the quarter, compared to analysts’ expectations of $49.52 billion. During the same period in the previous year, the firm posted $3.84 EPS. The business’s revenue for the quarter was up 9.6% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 25.500- EPS. Analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Wednesday, March 25th. Stockholders of record on Tuesday, March 10th will be issued a dividend of $1.72 per share. The ex-dividend date is Tuesday, March 10th. This is a boost from Elevance Health’s previous quarterly dividend of $1.71. This represents a $6.88 annualized dividend and a dividend yield of 2.1%. Elevance Health’s dividend payout ratio is 27.23%.

About Elevance Health

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.